$4.99
5.67% yesterday
Nasdaq, Aug 11, 10:15 pm CET
ISIN
US76029N1063
Symbol
REPL

Replimune Group, Inc. Target price 2025 - Analyst rating & recommendation

Replimune Group, Inc. Classifications & Recommendation:

Buy
47%
Hold
47%
Sell
7%

Replimune Group, Inc. Price Target

Target Price $4.08
Price $4.99
Deviation
Number of Estimates 10
10 Analysts have issued a price target Replimune Group, Inc. 2026 . The average Replimune Group, Inc. target price is $4.08. This is lower than the current stock price. The highest price target is , the lowest is .
A rating was issued by 15 analysts: 7 Analysts recommend Replimune Group, Inc. to buy, 7 to hold and 1 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Replimune Group, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Replimune Group, Inc. stock at Buy or hold.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2032

Create a premium account to unlock analyst estimates. Learn more

Mar '25 2026
Estimates
Earnings Per Share $ -3.07 -3.11
5.25% 1.30%
P/E negative
EV/Sales negative

11 Analysts have issued a Replimune Group, Inc. forecast for earnings per share. The average Replimune Group, Inc. EPS is

$-3.11
Unlock
. This is
14.34% lower
Unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-2.28 16.18%
Unlock
, the lowest is
$-3.68 35.29%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-3.07 5.25%
2026
$-3.11 1.30%
Unlock
2027
$-2.10 32.48%
Unlock
2028
$-1.37 34.76%
Unlock
2029
$-0.03 97.81%
Unlock
2030
$1.02 3,500.00%
Unlock
2031
$0.77 24.51%
Unlock
2032
$1.66 115.58%
Unlock

P/E ratio

Current -1.83 39.29%
2026
-1.70 12.59%
Unlock
2027
-2.52 48.24%
Unlock
2028
-3.87 53.57%
Unlock
2029
-194.24 4,919.12%
Unlock
2030
5.17 102.66%
Unlock
2031
6.87 32.88%
Unlock
2032
3.18 53.71%
Unlock

Current Replimune Group, Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Cantor Fitzgerald
Locked
Locked
Locked Jul 30 2025
Barclays
Locked
Locked
Locked Jul 23 2025
BMO Capital
Locked
Locked
Locked Jul 23 2025
HC Wainwright & Co.
Locked
Locked
Locked Jul 23 2025
Leerink Partners
Locked
Locked
Locked Jul 22 2025
Jefferies
Locked
Locked
Locked Jul 22 2025
JP Morgan
Locked
Locked
Locked Jul 22 2025
Analyst Rating Date
Locked
Cantor Fitzgerald:
Locked
Locked
Jul 30 2025
Locked
Barclays:
Locked
Locked
Jul 23 2025
Locked
BMO Capital:
Locked
Locked
Jul 23 2025
Locked
HC Wainwright & Co.:
Locked
Locked
Jul 23 2025
Locked
Leerink Partners:
Locked
Locked
Jul 22 2025
Locked
Jefferies:
Locked
Locked
Jul 22 2025
Locked
JP Morgan:
Locked
Locked
Jul 22 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today